The most groundbreaking individual studies from the latest supplement and nutrition research — in plain language, with the evidence caveats built in. Research signals worth knowing about, not health advice.
This is the first solid RCT linking Lactobacillus reuteri to a large reduction in gum pain and bone loss, but the effect is specific to periodontitis patients and needs replication before you should act on it.
This is one of the first meta-analyses to pool data on nigella seed for metabolic health, and the blood sugar drop is large enough to be clinically noticeable, though the lack of a fixed dose and the focus on already-sick patients means healthy people shouldn't expect the same effect.
Bacillus coagulans MTCC 5856 and Unique IS2 were ranked as top performers for reducing abdominal pain in a large meta-analysis, but because the dose was not reported and only three small studies underlie the finding, the result should be treated as promising but not definitive.
This is the first meta-analysis to link L-carnitine with major pain relief in osteoarthritis, but because it's early evidence and the exact dose used wasn't reported, the finding needs replication before you should act on it.
This is the first systematic review on folate for nerve pain, so while the effect is large and statistically significant, the missing dose detail and early-stage evidence mean it's promising but not yet definitive.
This study offers strong but preliminary evidence that combining whey protein with multicomponent exercise may help older adults with sarcopenia stand up from a chair more easily, a key functional outcome.
This is one of the first randomized trials to show a large, sustained drop in fasting blood sugar from curcumin in this specific population, but it's a single study with 114 people, so we'd want to see it replicated before getting too excited.